BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25746315)

  • 1. Approaches to improve development methods for therapeutic cancer vaccines.
    Ogi C; Aruga A
    Immunol Lett; 2015 Apr; 164(2):100-8. PubMed ID: 25746315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New concepts of biomarkers and clinical outcomes for therapeutic cancer vaccines in clinical trials.
    Ogi C; Aruga A
    Immunotherapy; 2014; 6(10):1025-36. PubMed ID: 25428643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roadmap to a better therapeutic tumor vaccine.
    Emens LA
    Int Rev Immunol; 2006; 25(5-6):415-43. PubMed ID: 17169782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current status and future perspective of cancer vaccine development].
    Sasada T; Itoh K
    Gan To Kagaku Ryoho; 2011 Apr; 38(4):503-8. PubMed ID: 21498975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in therapeutic cancer vaccines.
    Morse MA; Chui S; Hobeika A; Lyerly HK; Clay T
    Nat Clin Pract Oncol; 2005 Feb; 2(2):108-13. PubMed ID: 16264883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
    Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
    Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of therapeutic cancer vaccines.
    Ogi C; Aruga A
    Hum Vaccin Immunother; 2013 May; 9(5):1049-57. PubMed ID: 23454867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunotherapy of solid tumor: perspectives on vaccine and cell therapy].
    Ikeda H; Shiku H
    Nihon Rinsho; 2012 Dec; 70(12):2043-50. PubMed ID: 23259373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic vaccines for prostate cancer: recent advances and future directions.
    Strauss J; Madan RA
    Expert Rev Vaccines; 2016 Jul; 15(7):907-14. PubMed ID: 26889831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New directions in immunotherapy for malignant solid tumors].
    Okuno K; Sugiura F; Sukegawa Y; Inoue K
    Nihon Rinsho; 2012 Dec; 70(12):2075-86. PubMed ID: 23259377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of clinical trials for therapeutic cancer vaccines development.
    Mackiewicz J; Mackiewicz A
    Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vaccination strategies for solid tumors--fundamentals, limitations, and recent results].
    Atanackovic D
    Ther Umsch; 2004 Jun; 61(6):389-96. PubMed ID: 15253165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer vaccines. Any future?
    Myc LA; Gamian A; Myc A
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-13 receptor-directed cancer vaccines and immunotherapy.
    Nakashima H; Husain SR; Puri RK
    Immunotherapy; 2012 Apr; 4(4):443-51. PubMed ID: 22512637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell based cancer vaccines: regulatory and commercial development.
    Copier J; Ward S; Dalgleish A
    Vaccine; 2007 Sep; 25 Suppl 2():B35-46. PubMed ID: 17916462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer vaccine adjuvants--recent clinical progress and future perspectives.
    Banday AH; Jeelani S; Hruby VJ
    Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):1-11. PubMed ID: 25318595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies.
    Dalgleish AG
    Vaccine; 2011 Nov; 29(47):8501-5. PubMed ID: 21933695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy: new insights].
    Geissler M; Weth R
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2236-46. PubMed ID: 12564040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.